Supernus to Host Third Quarter 2015 Earnings Conference Call
October 20 2015 - 4:15PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system (CNS)
diseases, today announced that the Company expects to report the
financial results for the third quarter of 2015 after 5:00 PM ET on
Tuesday, November 3, 2015.
Jack Khattar, President and Chief Executive Officer and Greg
Patrick, Chief Financial Officer, will host a conference call to
present the third quarter 2015 results on Wednesday, November 4,
2015 at 9:00 AM ET. Following the presentation, the call will be
open for questions.
A live webcast will be available at www.supernus.com. Following
the live call, a replay will be available on the Company's website
under the 'Investors' section. The webcast will be available on the
Company's website for 60 days following the live call.
Please refer to the information below for conference call
dial-in information. Callers should dial in approximately 10
minutes prior to the start of the call.
Conference dial-in: |
(877) 288-1043 |
International dial-in: |
(970) 315-0267 |
Conference ID: |
64872787 |
Conference Call Name: |
Supernus Pharmaceuticals 3Q 2015 Earnings
Conference Call |
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases. The Company has two
marketed products for epilepsy, Oxtellar XR® (extended-release
oxcarbazepine) and Trokendi XR® (extended-release topiramate). The
Company is also developing several product candidates to address
large market opportunities in psychiatry, including SPN-810 for the
treatment of impulsive aggression in patients with ADHD in
conjunction with standard ADHD treatment and SPN-812 for ADHD.
CONTACT: Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024